GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (SSE:4502) » Definitions » EV-to-EBIT

Takeda Pharmaceutical Co (SSE:4502) EV-to-EBIT : 33.36 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Takeda Pharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Takeda Pharmaceutical Co's Enterprise Value is 円10,762,047 Mil. Takeda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円322,601 Mil. Therefore, Takeda Pharmaceutical Co's EV-to-EBIT for today is 33.36.

The historical rank and industry rank for Takeda Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:

SSE:4502' s EV-to-EBIT Range Over the Past 10 Years
Min: -44.38   Med: 23.79   Max: 102.85
Current: 33.37

During the past 13 years, the highest EV-to-EBIT of Takeda Pharmaceutical Co was 102.85. The lowest was -44.38. And the median was 23.79.

SSE:4502's EV-to-EBIT is ranked worse than
77.25% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs SSE:4502: 33.37

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Takeda Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円10,583,850 Mil. Takeda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円322,601 Mil. Takeda Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.05%.


Takeda Pharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Takeda Pharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co EV-to-EBIT Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.61 108.74 19.85 21.00 21.52

Takeda Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.56 21.52 21.22 30.46 33.19

Competitive Comparison of Takeda Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's EV-to-EBIT falls into.



Takeda Pharmaceutical Co EV-to-EBIT Calculation

Takeda Pharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10762046.594/322601
=33.36

Takeda Pharmaceutical Co's current Enterprise Value is 円10,762,047 Mil.
Takeda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円322,601 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co  (SSE:4502) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Takeda Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=322601/10583850.25
=3.05 %

Takeda Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円10,583,850 Mil.
Takeda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円322,601 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (SSE:4502) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (SSE:4502) Headlines

No Headlines